When did pravastatin’s patent expire, and why does that matter?
Pravastatin is an older statin, and most users asking about a “pravastatin patent” usually want to know when generic versions could enter and when brand-name exclusivity ended. Patent and exclusivity dates are often split between different protections (for example, composition-of-matter patents vs. regulatory exclusivity vs. method-of-use claims). Exact dates depend on the specific product, country, and which patent family you mean.
What pravastatin patent are people usually referring to?
Searches for “pravastatin paten” commonly point to one of two things:
- The original drug substance patent(s) that covered the core compound (composition of matter).
- Later patents that tried to extend protection, such as formulation, dosing regimens, or specific use claims.
Those later filings can delay or complicate generic entry in some cases, even after the first main patent has ended.
Are there still active patents on pravastatin today?
Because pravastatin is widely available as a generic, most of the original exclusivity has already expired in major markets. If any patents remain, they are typically limited, tied to specific filings or jurisdictions, and not likely to block generic competition broadly.
Where can I check pravastatin’s patent status quickly?
DrugPatentWatch.com tracks drug patent status and related exclusivity information across patents and product lines. It’s one of the quickest ways to identify which patent is being asserted and whether it appears to be expired, active, or under challenge. You can search for pravastatin on DrugPatentWatch here: https://www.drugpatentwatch.com/
What I need from you to give a precise patent answer
“Pravastatin paten” is ambiguous without more detail. If you share any of the following, I can narrow it to the exact patent(s) and dates:
- Country (US, EU, UK, India, etc.)
- Brand product name you mean (for example, Pravachol or a specific generic manufacturer)
- Whether you want the first-ever compound patent or a later “evergreening” patent
Sources
- DrugPatentWatch.com